Breaking Finance News

Leerink Partners upgraded Mirati Therapeutics (NASDAQ:MRTX) from Mkt Perform to Outperform in a report released today.

Leerink Partners has upgraded Mirati Therapeutics (NASDAQ:MRTX) from Mkt Perform to Outperform in a report released on 11/14/2017.

Previously on Tuesday September 19, 2017, Oppenheimer reported about Mirati Therapeutics (NASDAQ:MRTX) raised the target price from $0.00 to $18.00. At the time, this indicated a possible upside of 0.67%.

Yesterday Mirati Therapeutics (NASDAQ:MRTX) traded 1.29% higher at $13.05. The company’s 50-day moving average is $10.79 and its 200-day moving average is $5.83. The last stock close price is up 170.15% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 647,088 shares of the stock were exchanged, down from an average trading volume of 1,311,320

See Chart Below

Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics has a 52 week low of $2.70 and a 52 week high of $16.50 The company’s market cap is currently $0.

In addition to Leerink Partners reporting its stock price target, a total of 7 brokerages have issued a ratings update on the company. The average stock price target is $30.43 with 4 brokerages rating the stock a strong buy, 2 brokerages rating the stock a buy, 1 brokerage rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companyÂ’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *